A 48-WEEK, 6-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER TRIAL TO ASSESS THE SAFETY AND EFFICACY OF MULTIPLE CFZ533 DOSES ADMINISTERED SUBCUTANEOUSLY IN TWO DISTINCT POPLUATIONS OF PATIENTS WITH SJOGREN'S SYNDROME (TWINSS)

Registry ID

CCFZ533B2201

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2021-07-02

Last update

2019-12-20

Conditions

• SJOGREN'S SYNDROME

Related clinical trials

• A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER PHASE 3 PROTOCOL TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULTS WITH MODERATE TO SEVERE SJÖGREN'S DISEASE (SJD)
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAZODALIBEP IN PARTICIPANTS WITH SJOGREN'S SYNDROME WITH MODERATE TO SEVERE SYMPTON STATE
• A RANDOMIZED, DOUBLE-BLIND 2-ARM NEPTUNUS EXTENSION STUDY TO ACCESS THE LONG-TERM SAFETY AND EFFICACY OF IANALUMAB IN PATIENTS WITH SJOGREN'S SYNDROME

View on source registry